Skip to main navigation Skip to search Skip to main content

Scatter Factor/HGF and c-Met in Glioblastoma

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

The discovery of hepatocyte growth factor (HGF) in the early 1980s was followed by years of research into its role as an essential factor for normal human growth and development as well as its putative role in neoplasia signaling. The recognition that HGF and its tyrosine kinase receptor, mesenchymal-epithelial transition (MET) factor, constitute an essential signaling pathway in many cancers led to the development of corresponding targeted therapies. The signaling mediated by the HGF/c-Met system mediates crucial downstream effects in gliomas and is therefore considered a highly important target in these tumors. This review examines the research into the HGF/c-Met pathway in cancer with a focus on gliomas.

Original languageEnglish
Title of host publicationHandbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy
Subtitle of host publicationSecond Edition
PublisherElsevier Inc.
Pages341-346
Number of pages6
ISBN (Print)9780128121009
DOIs
StatePublished - Apr 24 2018

Keywords

  • Glioblastoma
  • Hepatocyte growth factor
  • Mesenchymal-epithelial transition factor
  • Receptor tyrosine kinase

Fingerprint

Dive into the research topics of 'Scatter Factor/HGF and c-Met in Glioblastoma'. Together they form a unique fingerprint.

Cite this